SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant /X/
Filed by a Party other than the Registrant / /

Check the appropriate box:

/X/ Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
/ / Definitive Proxy Statement
/ / Definitive Additional Materials
/ / Soliciting Material Pursuant to 240.14a-11(c) or 240.14a-12

GLOBAL PHARMACEUTICAL CORPORATION
- -----------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)

-----------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

/ / No fee required
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1) Title of each class of securities to which transaction applies:

----------------------------------------------------------------------
2) Aggregate number of securities to which transaction applies:

----------------------------------------------------------------------
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):

----------------------------------------------------------------------
4) Proposed maximum aggregate value of transaction:

----------------------------------------------------------------------

5) Total fee paid:

----------------------------------------------------------------------

/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.

1) Amount Previously Paid:

___________________________________________________________________________
2) Form, Schedule or Registration Statement No.:

___________________________________________________________________________
3) Filing Party:

___________________________________________________________________________
4) Date Filed:

___________________________________________________________________________

GLOBAL PHARMACEUTICAL CORPORATION

Dear Stockholder:

You are cordially invited to attend the Company's Annual Meeting of
Stockholders to be held on Wednesday, May 12, 1999 at 10:00 A.M., Eastern
Standard Time, at Mellon Bank Center, 1735 Market Street, 8th Floor, Forum Room,
Philadelphia, Pennsylvania.

The formal Notice of Meeting and the accompanying Proxy Statement set
forth proposals for your consideration this year. You are being asked to elect
directors, to act upon a proposal to approve certain amendments to the Company's
1995 Stock Incentive Plan, to act upon a proposal to approve an amendment to the
Certificate of Incorporation to increase the number of authorized shares and to
ratify the appointment of PricewaterhouseCoopers LLP as the independent
accountants of the Company.

At the meeting, the Board of Directors will also report on the affairs
of the Company, and a discussion period will be provided for questions and
comments of general interest to stockholders.

We look forward to greeting personally those of you who are able to be
present at the meeting. However, whether or not you are able to be with us at
the meeting, it is important that your shares be represented. Accordingly, you
are requested to sign, date and mail, at your earliest convenience, the enclosed
proxy in the envelope provided for your use.

Thank you for your cooperation.

Very truly yours,

BARRY R. EDWARDS
President and Chief Executive Officer

April 12, 1999

GLOBAL PHARMACEUTICAL CORPORATION
Castor and Kensington Avenues
Philadelphia, Pennsylvania 19124

---------------------------

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 12, 1999

---------------------------

To the Stockholders of Global Pharmaceutical Corporation:

NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of
Global Pharmaceutical Corporation (the "Company") will be held on Wednesday, May
12, 1999 at 10:00 A.M., Eastern Standard Time, at Mellon Bank Center, 1735
Market Street, 8th Floor, Forum Room, Philadelphia, Pennsylvania, for the
following purposes:

(1) To elect ten directors to serve for the ensuing year.

(2) To consider and act upon a proposal to approve
amendments to the Company's 1995 Stock Incentive Plan.

(3) To consider and act upon a proposal to amend the
Certificate of Incorporation to increase the number of authorized
shares.

(4) To consider and act upon a proposal to ratify the
appointment of PricewaterhouseCoopers LLP as the Company's independent
accountants for the fiscal year ending December 31, 1999.

(5) To transact such other business as may properly come
before the Annual Meeting or any adjournment thereof.

Only stockholders of record at the close of business on April 2, 1999
will be entitled to notice of and to vote at the Annual Meeting or any
adjournment thereof.

All stockholders are cordially invited to attend the Annual Meeting in
person. However, whether or not you plan to attend the Annual Meeting in person,
each stockholder is urged to complete, date and sign the enclosed form of proxy
and return it promptly in the envelope provided. No postage is required if the
proxy is mailed in the United States. Stockholders who attend the Annual Meeting
may revoke their proxy and vote their shares in person.

By Order of the Board of Directors

CORNEL C. SPIEGLER
Secretary

Philadelphia, Pennsylvania
April 12, 1999

GLOBAL PHARMACEUTICAL CORPORATION
Castor and Kensington Avenues
Philadelphia, Pennsylvania 19124

-----------------------------

PROXY STATEMENT

----------------------------

GENERAL INFORMATION

General

This Proxy Statement (first mailed to stockholders on or about April
12,1999) is furnished to the holders of Common Stock, par value $.01 per share
(the "Common Stock"), Series C Convertible Preferred Stock, par value $100 per
share (the "Series C Preferred"), and Series D Convertible Preferred Stock, par
value $100 per share (the "Series D Preferred"), of Global Pharmaceutical
Corporation (the "Company") in connection with the solicitation by the Board of
Directors of the Company of proxies for use at the Annual Meeting of
Stockholders (the "Annual Meeting"), or at any adjournment thereof, pursuant to
the accompanying Notice of Annual Meeting of Stockholders. The Annual Meeting
will be held on Wednesday, May 12, 1999 at 10:00 A.M., Eastern Standard Time, at
Mellon Bank Center, 1735 Market Street, 8th Floor, Forum Room, Philadelphia,
Pennsylvania.

It is proposed that at the Annual Meeting: (i) ten directors be
elected, (ii) the stockholders approve amendments to the Company's 1995 Stock
Incentive Plan (the "1995 Plan") adopted by the Board of Directors on March 22,
1999 which, subject to stockholders approval, (a) increase by 200,000 the number
of shares that may be issued thereunder, (b) provide for the periodic grant by
the Board of Directors in its sole discretion, of options to directors, (c)
reduce the annual automatic grant of options to non-employee directors who were
directors of the Company after September 1, 1995 from 10,000 to 5,000 shares,
and (d) limit the number of options which may be granted to any employee under
the 1995 Plan during any single calendar year to 100,000, (iii) an amendment to
the Certificate of Incorporation to increase the number of authorized shares be
approved, and (iv) the appointment of PricewaterhouseCoopers LLP as the
independent accountants of the Company for the fiscal year ending December 31,
1999 will be ratified.

Management currently is not aware of any other matters that will come
before the Annual Meeting. If any other matters properly come before the Annual
Meeting, the persons designated as proxies intend to vote in accordance with
their best judgment on such matters.

Proxies for use at the Annual Meeting are being solicited by the Board
of Directors of the Company. Proxies will be solicited chiefly by mail; however,
certain officers, directors, employees and agents of the Company, none of whom
will receive additional compensation therefor, may solicit proxies by telephone,
telegram or other personal contact. The Company will bear the cost of the
solicitation of the proxies, including postage, printing and handling, and will
reimburse the reasonable expenses of brokerage firms and others for forwarding
material to beneficial owners of shares of Common Stock, Series C Preferred and
Series D Preferred (collectively, the "Capital Stock")

Revocability and Voting of Proxy

A form of proxy for use at the Annual Meeting and a return envelope for
the proxy are enclosed. Unless otherwise indicated on the form of proxy, shares
of Capital Stock represented by any proxy in the enclosed form, assuming the
proxy is properly executed and received by the Company prior to the Annual
Meeting, will be voted with respect to the following items on the agenda: (i)
the election of each of the nominees for director as shown on the form of proxy
(ii) the approval of the proposed amendments to the 1995 Plan, (iii) the
adoption of the proposed amendment to the Certificate of Incorporation to
increase the number of authorized shares and (iv) the appointment of
PricewaterhouseCoopers LLP as the independent accountants of the Company.

Stockholders may revoke the authority granted by their execution of a
proxy at any time prior to the effective exercise of the powers conferred by
that proxy by filing with the Secretary of the Company a written notice of
revocation or a duly executed proxy bearing a later date or by voting in person
at the Annual Meeting. Shares of Capital Stock represented by executed and
unrevoked proxies will be voted in accordance with the instructions specified in
such proxies. If no specifications are given, the proxies intend to vote the
shares represented thereby "for" the election of each of the nominees for
director as shown on the form of proxy, "for" the approval of the proposed
amendments to the 1995 Plan, "for" the proposed amendment to the Certificate of
Incorporation to increase the number of authorized shares and "for" the
ratification of the appointment of PricewaterhouseCoopers LLP as the independent
accountants of the Company, and in accordance with their best judgment on any
other matters that may properly come before the meeting.

Record Date and Voting Rights

On April 2, 1999, there were 7,254,053 shares of Common Stock, 9,000
shares of Series C Preferred and 30,000 shares of Series D Preferred
outstanding. Only stockholders of record at the close of business on April 2,
1999 (the "Record Date") are entitled to notice of and to vote at the Annual
Meeting or any adjournment thereof.

Each share of Common Stock is entitled to one vote upon each of the
matters to be presented at the Annual Meeting. The holders of shares of Series C
Preferred and Series D Preferred vote, in general, as a single class with the
holders of the Common Stock, on all matters voted on by the stockholders of the
Company, with each holder of Series C Preferred or Series D Preferred entitled
to the number of shares of Common Stock into which that holder's shares would
then be convertible. At the Record Date, each share of Series C Preferred and
Series D Preferred was convertible into 50 shares of Common Stock. Accordingly,
as of the Record Date, the holders of the shares of Common Stock, Series C
Preferred and Series D Preferred are entitled to cast a total of 9,204,053
votes.

The affirmative vote of the holders of a plurality of the shares
present in person or represented by proxy and entitled to vote at the Annual
Meeting is required for the election of directors. The affirmative vote of the
holders of a majority of the shares present in person or represented by proxy
and entitled to vote at the Annual Meeting is required for the approval of the
amendments to the 1995 Plan and of the ratification of the appointment of
PricewaterhouseCoopers LLP. The affirmative vote of the holders of a majority of
the shares entitled to vote at the annual meeting is required for the approval
of the amendment to the Certificate of Incorporation to increase the number of
authorized shares.

Abstentions and broker non-votes will be counted for purposes of
determining the presence or absence of a quorum, but will not be counted with
respect to the specific matter being voted upon. As a result, abstentions from
the vote to consider the adoption of the amendments to the 1995 Plan, of the
amendment to the Certificate of Incorporation to increase the number of
authorized shares and the ratification of the appointment of
PricewaterhouseCoopers LLP and broker non-votes are effectively treated as votes
against the proposals, making it more difficult to obtain the necessary approval
for these proposals.

"Broker non-votes" are shares held by brokers or nominees which are present
in person or represented by proxy, but which are not voted on a particular
matter because instructions have not been received from the beneficial owner.

BENEFICIAL OWNERSHIP OF COMMON STOCK BY
CERTAIN STOCKHOLDERS AND MANAGEMENT

The following table sets forth information as of March 16, 1999 (except
as otherwise noted in the footnotes) regarding the beneficial ownership of the
Company's Capital Stock of: (i) each person known by the Company to own
beneficially more than five percent of the outstanding Common Stock, Series C
Preferred or Series D Preferred; (ii) each director and nominee for election as
a director of the Company; (iii) each executive officer named in the Summary
Compensation Table (see "Executive Compensation"); and (iv) all directors and
executive officers of the Company as a group. Except as otherwise specified, the
named beneficial owner has the sole voting and investment power over the shares
listed.

Common Stock Series C Preferred Stock** Series D Preffered Stock**
----------------------- -------------------------- --------------------------
Name and Address of Beneficial Owner No of Shares Percent No of Shares Percent No of Shares Percent
- ------------------------------------ ------------ ------- ------------ ------- ------------ -------

Robert L. Burr (1).............................. 0 0 0
c/o Fleming Capital Management
Robert Fleming, Inc.
320 Park Avenue
New York, NY 10022

Philip R. Chapman (2)........................... 14,031 * 0 0
c/o Venad Administrative Services, Inc.
342 Madison Avenue - Suite 807
New York, NY 10173

David J. Edwards (1)............................ 0 0 0
c/o Fleming Capital Management
Robert Fleming, Inc.
320 Park Avenue
New York, NY 10022

Barry R. Edwards (3)............................ 43,708 * 0 0
Castor & Kensington Avenues
Philadelphia, PA 19124

Gary Escandon (4)............................... 124,894 1.7 0 0
c/o Alvaro P. Escandon, Inc.
17 Prospect Street
Highlands, NJ 07732

G. Thomas Finnegan ............................. 0 0 0
c/o Fincoh Partners, LP
908 Calibre Woods Drive
Atlanta, GA 30329

George F. Keane(5).............................. 51,333 * 0 0
c/o Trigen Energy Corporation
237 Mayfield Drive
Trumbull, CT 06611

Michael Markbreiter(6)............................. 3,333 * 0 0
c/o Kingdon Capital Management Corp.
152 West 57th Street
New York, NY 10019

Max L. Mendelsohn(7)............................ 165,766 2.3 0 0
c/o Global Pharmaceutical Corporation
Castor and Kensington Avenues
Philadelphia, PA 19124

John W. Rowe, M.D.(8)........................... 43,333 * 0 0
c/o Mount Sinai - NYU
Medical Center and Health System
One Gustave L. Levy Place
New York, NY 10029

Udi Toledano(9)................................. 242,592 3.3 0 0
545 Madison Avenue
Suite 800
New York, NY 10022

Marc Feinberg(10)............................... 35,136 * 0 0
c/o Global Pharmaceutical Corporation
Castor and Kensington Avenues
Philadelphia, PA 19124

Seymour Hyden, Ph.D. (11)....................... 26,341 * 0 0
c/o Global Pharmaceutical Corporation
Castor and Kensington Avenues
Philadelphia, PA 19124

Cornel Spiegler(12)............................. 48,504 * 0 0
c/o Global Pharmaceutical Corporation
Castor and Kensington Avenues
Philadelphia, PA 19124

Joseph A. Storella(13).......................... 41,000 * 0 0
c/o Global Pharmaceutical Corporation
Castor and Kensington Avenues
Philadelphia, PA 19124

Frederick R. Adler (14)......................... 729,345 10.0 0 0
c/o Venad Management, Inc.
1520 South Ocean Boulevard
Palm Beach, FL 33480

Bear Stearns Asset Management Inc. (15)...... 985,253 13.2 9,000 100 0
575 Lexington Avenue
New York, NY 10167

Robert Fleming Inc. (16).......................... 1,875,000 20.5 0 30,000 100
Fleming US Discovery Fund III, L.P................ 1,616,000 17.7 0 25,856 86.2
Fleming US Discovery Offshore Fund III, L.P....... 259,000 2.8 0 4,144 13.8
c/o Robert Fleming, Inc.
320 Park Avenue, 11th Floor
New York, NY 10022

Kingdon Capital Management Corporation(17)...... 1,882,353 25.9 0 0
Kingdon Offshore N.V.............................. 1,129,412 15.5 0 0
Kingdon Associates, L.P........................... 376,471 5.2 0 0
Kingdon Partners, L.P............................. 376,470 5.2 0 0
c/o Kingdon Capital Management Corp.
152 West 57th Street
New York, NY 10019

All directors and executive officers as a group
(15 Persons) (2) - (13)........................... 905,323 12.5 0 0

- ----------------------------
* Less than one percent.
** At the option of each holder, as of March 16,1999, each share of Series C
Preferred and Series D Preferred was convertible at any time into 50 shares
of the Company's Common Stock.

(1) Messrs. Robert Burr and David Edwards are employees of Fleming
Capital Management, a subsidiary of Robert Fleming, Inc. See also Note
16.

(2) Includes options to purchase 1,667 shares of Common Stock which may
be exercised within 60 days. Does not include 50,000 shares of Common
Stock owned by a limited partnership of which Mr. Chapman's wife is the
sole general partner and 575,350 shares of Common Stock held by the
Frederick R. Adler Intangible Asset Management Trust, of which Mr.
Chapman's wife serves as trustee.

(3) Includes options to purchase 42,708 shares of Common Stock which
may be exercised within 60 days.

(4) Includes 7,500 shares of Common Stock owned by the Alvaro P.
Escandon Inc. Money Purchase Pension Plan dated 12/1/80, with respect
to which Mr. Escandon disclaims beneficial ownership. Also includes
options to purchase 1,667 shares of Common Stock and a warrant to
purchase 3,500 shares of Common Stock which may be exercised within 60
days.

(5) Includes options immediately exercisable for 43,333 shares of
Common Stock.

(6) Consists of options immediately exercisable for 3,333 shares of
Common Stock. Does not include shares beneficially owned by Kingdon
Capital Management Corporation ("KCMC"), the general partner of M.
Kingdon Offshore, N.V., Kingdon Associates, L.P. and Kingdon Partners,
L.P. (collectively, "Kingdon"), with which Mr. Markbreiter is
associated.

(7) Includes options to purchase 70,000 shares of Common Stock and a
warrant to purchase 3,500 shares of Common Stock which may be exercised
within 60 days.

(8)Consists of options immediately exercisable for 43,333 shares of
Common Stock.

(9) Includes 68,568 shares of Common Stock owned by Mr. Toledano's wife
and 22,529 shares of Common Stock owned by a trust for the benefit of
minor children of Mr. Toledano, all of which shares Mr. Toledano
disclaims beneficial ownership. Also includes options to purchase 1,667
shares of Common Stock and a warrant to purchase 14,000 shares of
Common Stock exercisable within 60 days.

(10) Includes options to purchase 31,000 shares of Common
Stock which may be exercised within 60 days.

(11) Includes options to purchase 23,000 shares of Common
Stock which may be exercised within 60 days.

(12) Includes options to purchase 36,667 shares and a warrant to
purchase 3,500 shares of Common Stock which may be exercised within 60
days.

(13) Includes options to purchase 36,000 shares of Common
Stock which may be exercised within 60 days.

(14) Includes 136,495 shares of Common Stock held by 1520 Partners,
Ltd., a limited partnership of which Mr. Adler is the general partner
and 575,350 shares of Common Stock held by Frederick R. Adler
Intangible Asset Management Trust. Mr. Adler may be deemed to be the
beneficial owner of the shares of Common Stock held by 1520 Partners,
Ltd. and the Frederick R. Adler Intangible Asset Management Trust, with
respect to which shares Mr. Adler disclaims beneficial ownership. Also
includes a warrant to purchase 17,500 shares of Common Stock which may
be exercised within 60 days.

(15) The source of this information is the Schedule 13G, dated March
10, 1999 filed with the Securities and Exchange Commission. Such
Schedule 13G reported that Bear Stearns Asset Management, Inc. has sole
power to dispose or direct the disposition of 1,435,253 shares which is
beneficially owned. Includes 450,000 shares of Common Stock which are
issuable upon the conversion of 9,000 shares of Series C Preferred and
a warrant to purchase 225,000 shares of Common Stock which may be
exercised within 60 days.

(16) Consists of 1,500,000 shares of Common Stock which are issuable
upon the conversion of 30,000 shares of Series D Preferred and warrants
to purchase an aggregate of 375,000 shares of Common Stock which may be
exercised within 60 days. Does not include an aggregate of 20,000
shares of Series D Preferred (convertible into 1,000,000 shares of
Common Stock) and warrants to purchase 250,000 shares of Common Stock,
which the Company has agreed to sell prior to June 30, 1999, subject to
stockholder approval of Proposal No. 3 below.

(17) KCMC, the general partner, Kingdon, is deemed to be the beneficial
owner of the 1,882,353 shares of Common Stock held by Kingdon.

PROPOSAL NO. 1--ELECTION OF DIRECTORS

Ten directors (constituting the entire Board) are to be
elected at the Annual Meeting. Unless otherwise specified, the enclosed proxy
will be voted in favor of the persons named below to serve until the next annual
meeting of stockholders and until their respective successors shall have been
duly elected and qualified. If any of these nominees becomes unavailable for any
reason, or if a vacancy should occur before the election, the shares represented
by the proxy will be voted for the person, if any, who is designated by the
Board of Directors to replace the nominee or to fill the vacancy on the Board.
All nominees have consented to be named and have indicated their intent to serve
if elected. The Board of Directors has no reason to believe that any of the
nominees will be unable to serve or that any vacancy on the Board of Directors
will occur.

The nominees, their ages and the year in which each became a director and their
principal occupations or employment during the past five years are as follows:

Director
Name Age Since Position
---- --- -------- --------
Robert L. Burr................ 48 -- Director Nominee

Philip R. Chapman............. 37 1995 Director

Barry R. Edwards ............. 42 1999 President, Chief Executive
Officer and a Director

David J. Edwards.............. 33 -- Director Nominee

Gary Escandon................. 51 1995 Director

George F. Keane............... 69 1995 Director

Michael Markbreiter........... 36 1997 Director

Max L. Mendelsohn............. 65 1993 Chairman and Director

John W. Rowe, M.D. ........... 54 1995 Director

Udi Toledano.................. 48 1995 Director
- ------------------

Robert L. Burr has been a director of Fleming Capital Management, a
subsidiary of Robert Fleming Inc., an investment bank, since 1995. From 1992 to
1995, Mr. Burr was head of Private Equity at Kidder, Peabody & Co., Inc. Prior
to that time, Mr. Burr served as the Managing General Partner of Morgan Stanley
Ventures and was a corporate lending officer with Citibank, N.A. Mr. Burr
received an MBA from Columbia University and a BA from Stanford University.

Philip R. Chapman has been a principal in Adler & Company, a venture
capital management firm, since 1991 and became a General Partner in 1995. Mr.
Chapman is the son-in-law of Frederick R. Adler, a beneficial owner of greater
than 5% of the outstanding voting shares. Prior to joining Adler & Company, Mr.
Chapman was a senior consultant with Booz Allen & Hamilton International, a
management consulting company based in London. Since May 1997, Mr. Chapman has
served as a director of Shells Seafood Restaurants, Inc., a chain of seafood
restaurants. Mr. Chapman has served as a director of Integrated Packaging
Assembly Corp., a semi-conductor packaging company, as well as of a number of
private companies. Mr. Chapman served as Executive Vice President and President
of the Company during a portion of 1995.

Barry R. Edwards has been President since August 1998 and Chief Executive
Officer and a director of the Company since January 1999. From 1996 to 1998, Mr.
Edwards was Vice President, Marketing and Business Development for Teva
Pharmaceuticals USA, a manufacturer of generic drugs. From 1991 to 1996, Mr.
Edwards served as Executive Director of Gate Pharmaceuticals, a division of Teva
Pharmaceuticals USA. Prior to 1991, Mr. Edwards held a number of management
functions in strategic planning, corporate development, business development and
marketing at Teva Pharmaceuticals USA.

David J. Edwards has been a Vice President at Fleming Capital Management
since 1994. Prior to that time, Mr. Edwards was an Associate with Booz Allen &
Hamilton, a strategic management consulting company based in New York. From 1987
to 1990 Mr. Edwards was a Process Engineer with Exxon Chemical Corporation. Mr.
Edwards received an MBA from Harvard Business School and a Masters in
Engineering from Cambridge University.

Gary Escandon is President of Alvaro P. Escandon Inc., a domestic and
international supplier of home furnishing textile piece goods that he organized
in 1978. From 1991 to 1995, Mr. Escandon was President of Refreshment Service
Corp. and from 1974 to 1978, served as Director of Sales Promotion at The Mennen
Company, a manufacturer of health and beauty aids. From 1972 to 1974, Mr.
Escandon served as Sales Promotion Coordinator at Bristol-Myers Company. Mr.
Escandon has served on the Board of Trustees of Muhlenberg College since 1993.

George F. Keane has been Chairman of the Board of Trigen Energy (TGN) since
1994. Previously, Mr. Keane was the founding chief executive officer of The
Common Fund in 1971, and of Endowment Advisers, Inc. and Endowment Realty
Investors in 1988. He served as President of these nonprofit organizations until
1993. Now called Commonfund Group, these organizations manage over $20 billion
in endowment and operating funds for more than 1200 colleges throughout the U.S.
Mr. Keane also serves on several other boards, including as Director of Northern
Trust of Connecticut since 1991, Nicholas-Applegate Investment Trust since 1993,
the Bramwell Mutual Funds since 1994, Universal Stainless & Alloy Products since
1994, the Universal Bond Fund since 1995, and United Water Resources and its
affiliated companies since 1995. Mr. Keane also serves as a member of the
Investment Advisory Committee for the $100 billion New York State Common
Retirement Fund, is Chairman of the Investment Committee of the United Negro
College Fund, and is Vice Chairman of his alma mater Fairfield University.

Michael Markbreiter has been a portfolio manager for private equity
investments for Kingdon Capital Management Corp., a manager of investment fund
since August 1995. In April 1994, Mr. Markbreiter co-founded Ram Investment
Corp., a venture capital company. From March 1993 to January 1994, Mr.
Markbreiter served as a portfolio manager for Kingdon Capital Management Corp.
From December 1989 to February 1993, Mr. Markbreiter was an analyst at Alliance
Capital Management Corp. From July 1993 to September 1989, Mr. Markbreiter was
an Executive Editor for Arts of Asia magazine. Mr. Markbreiter has served as a
Director of Alyn Corporation, an advanced materials producer, since May 1996.
Mr. Markbreiter graduated from Cambridge University with a degree in
Engineering.

Max L. Mendelsohn has been Chairman of the Company since August 1998. From
1995 to 1998, Mr. Mendelsohn was President and Chief Executive Officer of the
Company. From 1970 to 1990, Mr. Mendelsohn was President and Chief Executive
Officer of Barre-National, Inc., a manufacturer of liquid pharmaceutical
products. From 1991 to 1995, Mr. Mendelsohn served as Vice President of Business
Development of Pharmakinetics Laboratories, Inc., a provider of clinical and
analytical services to United States and Canadian pharmaceutical companies. Mr.
Mendelsohn has been a director of the Generic Pharmaceutical Industry
Association since 1987 and has served as Secretary-Treasurer of that
organization since March 1997.

John W. Rowe, M.D. is President and Chief Executive Officer of The Mount
Sinai School of Medicine and The Mount Sinai - NYU Medical Center and Health
System in New York City, where he also serves as a Professor of Medicine and of
Geriatrics and Adult Development. Before joining Mount Sinai in 1988, Dr. Rowe
was Professor of Medicine and the founding Director of the Division on Aging at
Harvard Medical School and Chief of Gerontology at Beth Israel Hospital. He has
authored over 200 scientific publications, most of them concerning the basic
biology and physiology of the aging process, as well as several textbooks on
geriatric medicine. Since 1985, Dr. Rowe has been a director of the MacArthur
Foundation Research Network on Successful Aging. From 1987 to 1993, Dr. Rowe
served on the Board of Governors of the American Board of Internal Medicine.
Since 1989, Dr. Rowe has been a member of the Institute of Medicine of the
National Academy of Sciences and Chair, Council on Biomedical Research and
Development of the New York Academy of Medicine. Dr. Rowe has been a participant
and a member of numerous medical committees and advisory panels and is the
recipient of many awards and honors within the medical community.

Udi Toledano has been the President of Andromeda Enterprises, Inc., a
private investment company, since December 1993. From 1983 to December 1993, he
was the president of CR Capital Inc., a private investment company. Mr. Toledano
has served on boards of both public and private companies in various fields
including healthcare and technology. Mr. Toledano has been a director of
Universal Stainless & Alloy Products, Inc., a manufacturer of specialty steel
products, since July 1994.

Committees

The Board of Directors of the Company has an Executive Committee, Audit
Committee, Compensation Committee and Stock Option Committee. During the fiscal
year ended December 31, 1998, each director then in office, except for Mr.
Michael Markbreiter, attended not less than 75% of the aggregate number of
meetings of the Board of Directors and meetings of the committee of the Board on
which he served which were held while such person served in office. The Board of
Directors held four meetings during the fiscal year ended December 31, 1998.

The Executive Committee, established in September 1995, consisted of
Messrs. Mendelsohn, Chapman, Escandon, Markbreiter and Toledano during the
fiscal year 1998. The Executive Committee has all the powers of the Company's
Board of Directors except that it is not authorized to amend the Company's
Certificate of Incorporation, declare any dividends or issue shares of the
capital stock of the Company. The Executive Committee held eight meetings during
the fiscal year ended December 31, 1998. During the fiscal year ended December
31, 1998, each member of the Executive Committee attended not less than 75% of
the aggregate number of meetings of this committee. In January 1999, Mr. Barry
Edwards replaced Mr. Mendelsohn as a member of the Executive Committee.

The Audit Committee, established in October 1995, currently consists of Mr.
Toledano, as Chairman, and Messrs. Chapman, Escandon and Keane and Dr. Rowe. The
Audit Committee reviews with the Company's independent accountants the scope and
timing of their audit services, any other services they are asked to perform,
the report of independent accountants on the Company's financial statements
following completion of their audit and the Company's policies and procedures
with respect to internal accounting and financial controls. In addition, the
Audit Committee makes an annual recommendation to the Board of Directors
concerning the appointment of independent accountants for the ensuing year. The
Audit Committee met one time during the fiscal year ended December 31, 1998 with
all members of the Committee in attendance except for Mr. Keane and Dr. Rowe.

The Compensation Committee, established in October 1995, consisted of Mr.
Escandon, as Chairman, and Messrs. Keane and Mendelsohn. The Compensation
Committee reviews and makes recommendations to the Board of Directors regarding
the compensation and benefits of all officers of the Company and reviews general
policy matters relating to compensation and benefits of employees of the

Company. Prior to the formation of the Stock Option Committee in March 1997, the
Compensation Committee also administered the 1995 Plan. The Compensation
Committee met four times during the fiscal year ended December 31, 1998 with all
members of the Committee in attendance. In January 1999, Mr. Barry Edwards
replaced Mr. Mendelsohn as a member of the Compensation Committee.

The Stock Option Committee, established in March 1997, currently consists
of Mr. Escandon, as Chairman, and Mr. Keane. Except with regard to director
options, the Committee reviews the stock option benefits of all officers of the
Company and other participants in the 1995 Plan, reviews general policy matters
relating to stock options, grants stock options to officers of the Company and
other participants in the 1995 Plan and administers the 1995 Plan. The Stock
Option Committee met four times during the fiscal year ended December 31, 1998
with all members of the committee in attendance

In March 1997, the Board of Directors authorized the formation of the
Scientific Advisory Board to be chaired by Dr. Rowe. The Scientific Advisory
Board has not held a meeting to date. See "Certain Relationships and Related
Transactions".

Compensation of Directors

Members of the Board of Directors of the Company received no annual
remuneration for acting in that capacity during the fiscal year ended December
31, 1998. The Company's non-employee directors were paid $500 (plus reasonable
expenses) for each attended meeting of the Board of Directors. Pursuant to the
terms of the 1995 Plan, each non-employee director who was not a director of the
Company on or before September 1, 1995 was granted an option to purchase 10,000
shares of Common Stock on the first business day after the Annual Meeting of
Stockholders at which such non-employee director was elected (including
re-elections) or, if elected at another time, on the date of such election.
Under the 1995 Plan, each non-employee director who was a director of the
Company prior to September 1, 1995 is similarly granted an option to purchase
5,000 shares of Common Stock. In May 1998, pursuant to the 1995 Plan, each of
Mr. Keane and Dr. Rowe were granted options to purchase 10,000 shares of Common
Stock at an exercise price of $4.125 per share and each of Messrs. Chapman,
Escandon and Toledano received options to purchase 5,000 shares at an exercise
price of $4.125 per share.

On March 22, 1999, the Board of Directors adopted certain amendments (the
"Amendments") to the 1995 Plan, which Amendments are presented to the
stockholders as Proposal No. 2 hereof. Among other things, the Amendments
provide for the periodic grant by the Board of Directors, in its sole
discretion, of options to directors and reduce the annual grant of options to
non-employee directors who were directors of the Company after September 1, 1995
from 10,000 to 5,000 shares. In the event that these Amendments to the 1995 Plan
are approved, each non-employee director will receive such annual grant of
options to purchase 5,000 shares, as well as, if elected, the director nominees.
Subject to the approval of the Amendments, on March 22, 1999, Messrs. Chapman,
Escandon and Toledano were each granted options to purchase 20,000 shares of
Common Stock at an exercise price of $2.0625 per share and Mr. Markbreiter has
been granted options to purchase 10,000 shares of Common Stock at an exercise
price of $2.0625 per share. These option grants were made to such individuals
in their capacity as members of the Executive Committee in recognition of their
significant time commitments and efforts over the past year on behalf of the
Company.

Section 16(a) Beneficial Ownership Reporting Compliance

To the Company's knowledge, the Company's directors, officers and
beneficial owners of ten percent or more of the Company's Common Stock are in
compliance with the reporting requirements of Section 16(a) under the Securities
Exchange Act of 1934, as amended, except for a Schedule 13D by Kingdon Capital
Management Corp.

Vote Required

The ten nominees receiving the highest number of affirmative votes of the
shares present in person or represented by proxy and entitled to vote for them
shall be elected as directors. Only votes cast for a nominee will be counted,
except that the accompanying proxy will be voted for all nominees in the absence
of instructions to the contrary. Abstentions, broker non-votes and instructions
on the accompanying proxy card to withhold authority to vote for one or more
nominees will not be counted as a vote for any such nominee.

THE BOARD OF DIRECTORS DEEMS THE ELECTION AS DIRECTORS OF THE TEN NOMINEES
LISTED ABOVE TO BE IN THE BEST INTERESTS OF THE COMPANY AND ITS STOCKHOLDERS AND
RECOMMENDS A VOTE "FOR" THE ELECTION OF EACH OF THESE NOMINEES.

EXECUTIVE COMPENSATION

The following table summarizes the compensation earned by or paid to the
Company's current and former President and Chief Executive Officer and the
Company's other four most highly compensated executive officers for 1996, 1997
and 1998.

SUMMARY COMPENSATION TABLE

Annual Long-Term
Compensation Compensation
-------------------------------------------------------- --------------------
Name and Principal Position Year Salary ($) Bonus ($) Other Annual Common Stock
--------------------------- ---- ---------- --------- ------------ ------------
Compensation ($) Underlying Options(#)
---------------- ---------------------

Barry R. Edwards, President and 1998 93,363(1) 10,000(2) 5,472(3) 62,175
Chief Executive Officer (since
January 1999) .........................

Max L. Mendelsohn, President and 1998 160,818 1,650 18,063(4) 40,650
Chief Executive Officer *............. 1997 153,578 -- 18,172(4) 65,000(11)
1996 150,001(5) -- 23,368(4)

Cornel C. Spiegler, Chief Financial 1998 138,817 1,391 -- 10,870
Officer and Vice 1997 135,660 -- -- 36,000(11)
President--Administration............. 1996 131,144(6) 25,000(7) --

Joseph A. Storella, Vice President - 1998 135,985 1,365 -- 10,000
Operations............................ 1997 133,100 -- -- 36,000(11)
1996 78,500(8) -- --

Marc M. Feinberg, Vice President - 1998 133,499 1,365 -- 36,000 (11)
Quality Assurance and Regulatory 1997 133,100 -- --
Affairs .............................. 1996 26,000(9) -- --

Seymour Hyden, Ph.D. Vice President 1998 127,760(1) 1,300 13,943(11)
- - Scientific and Technical Affairs 1997 88,207 -- 15,003(11) 36,000(11)

- ----------------------

* Mr. Mendelsohn served as President and Chief Executive Officer
of the Company from September 1995 through January 1999.
(1) Mr. Edwards joined the Company in April 1998 as Executive Vice
President and became President and Chief Executive Officer of the
Company in January 1999.

(2) Represents sign-on bonus.
(3) Represents life insurance and long term disability along with gross-up
tax payments with respect to such insurance payments and $3,336 in car
allowance.
(4) Represents life insurance and long-term disability insurance along with
gross-up tax payments with respect to such insurance payments.
(5) The salary includes $28,558 that was earned by Mr. Mendelsohn in 1995
and paid to him in 1996.
(6) Mr. Spiegler has served as Chief Financial Officer and Vice President -
Administration of the Company since September 1995.
(7) Bonus earned in 1995 and paid in 1996.
(8) Mr. Storella has served as Vice President - Operations of the Company
since May 1996.
(9) Mr. Feinberg has served as Vice President - Quality Assurance and
Regulatory Affairs since October 1996.
(10) Dr. Hyden served as Vice President - Scientific and Technical Affairs
from March 1997 through March 1999.
(11) Represents cancellation of Old Options and the issuance of identical
repriced New Options having an exercise price of $3.125 per share.

The following table sets forth information on option grants in the
fiscal year ended December 31, 1998 to the persons named in the Summary
Compensation Table.

OPTION GRANTS IN LAST FISCAL YEAR

% of Total Options
Number of Securities Granted to
Underlying Options Employees in Exercise
Name Granted Fiscal Year Price ($/SH) Expiration Date
- ---- -------------------- ----------------- ------------ ---------------

Barry R. Edwards......... 50,000 23.3 5.00 03/25/08
12,175 5.7 2.00 11/19/08

Max L. Mendelsohn........ 25,000 11.7 3.75 01/27/08
15,650 7.3 2.00 11/19/08

Cornel C. Spiegler....... 10,870 5.1 2.00 11/19/08

Joseph A. Storella....... 10,000 4.7 2.00 11/19/08

Marc M. Feinberg......... -- -- -- --

Seymour Hyden, Ph.D...... -- -- -- --

- ---------------------------------

The following table sets forth information with respect to unexercised
stock options held at December 31, 1998 by the persons named in the Summary
Compensation Table. There were no exercises of options to purchase Common Stock
by such individuals during the fiscal year ended December 31, 1998.

AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND
FISCAL YEAR-END OPTION VALUES

Number of Unexercised Value of Unexercised
Options Held at in-the-Money Options at
Fiscal Year End (#) Fiscal Year End($)(1)
------------------------------ ------------------------------
Name Exercisable Unexercisable Exercisable Unexercisable
- ---- ----------- ------------- ----------- -------------

Barry R. Edwards ............ 12,500 37,500 0 (1) 0 (1)
0 12,175 0 4,566 (2)
Max L. Mendelsohn............ 70,000 20,000 0 (3) 0 (3)
0 15,650 0 (4) 5,869 (2)
Cornel C. Spiegler........... 36,000 10,870 0 4,076 (2)

Joseph A. Storella........... 31,000 15,000 0 (4) 3,750 (2)
Marc M. Feinberg............. 26,000 10,000 0 (4) 0 (4)
Seymour Hyden, Ph.D.......... 21,000 15,000 0 (4) 0 (4)

- ---------------------------------

(1) Computed based on the difference between the closing bid price per
share of the Common Stock of $2.375 on December 31, 1998 and the exercise price
of $5.00.
(2) Computed based on the difference between the closing bid price per
share of the Common Stock of $2.375 on December 31, 1998 and the exercise price
of $2.00.
(3) Computed based on the difference between the closing bid price per
share of the Common Stock of $2.375 on December 31, 1998 and the exercise prices
of $3.125 and $3.75, respectively.
(4) Computed based on the difference between the closing bid price per
share of the Common Stock of $2.375 on December 31, 1998 and the exercise price
of $3.125.

Employment Agreements

Barry R. Edwards has entered into a three-year employment agreement with
the Company for the position of Executive Vice President effective March 1998.
Mr. Edwards' employment agreement provides for a base annual salary of $145,000,
which may be increased annually at the discretion of the Board of Directors, as
well as stock options and a customary benefits package. Under Mr. Edwards'
employment agreement, the Company will pay him a $10,000 sign-on bonus and he is
eligible to participate in an incentive bonus program of up to 24% of his base
salary in accordance with pre-established individual, corporate and business
goals. The $10,000 sign-on bonus was paid to Mr. Edwards in May 1998; no other
incentive bonus amounts were paid in 1998. In connection with his employment
contract, the Company granted Mr. Edwards an option to purchase 50,000 shares of
Common Stock at $5.00 per share. One-fourth of the options vests on March 25,
1998, one-fourth vests on March 25, 1999 and the remaining one-half vests in
monthly installments over the 24-month period beginning on March 25, 1999, in
each case based on Mr. Edwards' continued employment during that time.

In January 1999, Mr. Edwards became the Company's President and Chief
Executive Officer.

Max L. Mendelsohn, Pieter J. Groenewoud and Cornel C. Spiegler have entered
into three-year employment agreements with the Company for the position of
President and Chief Executive Officer; Vice President, Product Development; and
Chief Financial Officer and Vice President--Administration; respectively,
effective September 1995, May 1996, and September 1995. Messrs. Mendelsohn's,
Groenewoud's and Spiegler's employment agreements provide for a base annual
salary of $150,000, $90,000 and $125,000, respectively, which may be increased
annually at the discretion of the Board of Directors, as well as stock options
and a customary benefits package. Under Mr. Mendelsohn's employment agreement,
he may be eligible for a performance-based bonus equal to $30,000 which amount
was not earned in 1998.

At the Company's option, the term of each of Messrs. Mendelsohn's,
Groenewoud's and Spiegler's employment agreement may be extended for one
additional year. The employment agreements of Messrs. Mendelsohn, Groenewoud and
Spiegler prohibit them from (i) competing with the Company for one year
following termination of employment with the Company and (ii) disclosing
confidential information or trade secrets in any unauthorized manner. If one of
those employees is discharged without cause (as defined in such employee's
agreement), the Company shall continue to pay such employee at his then current
salary for the longer of six months or the remainder of the agreed upon
employment period.

In connection with his employment agreement, the Company granted Mr.
Mendelsohn an option to purchase 12,500 shares of Common Stock at $5.75 per
share and granted to him in December 1995 an additional option to purchase
52,500 shares of Common Stock at $8.50 per share. The options vest in equal
monthly installments on the last day of each month occurring in the 36-month
period beginning September 1, 1995, subject to Mr. Mendelsohn's continued
employment. The options will become fully vested if Mr. Mendelsohn's employment
is terminated under certain circumstances, including a termination by the
Company without cause. In conjunction with the repricing of all of the Company's
stock options, Mr. Mendelsohn's options were cancelled effective December 19,
1997 and replaced with identical repriced New Options having an exercise price
of $3.125 per share. On January 27, 1998, Mr. Mendelsohn's employment agreement
was extended by two years through September 1, 2000 at an annual salary of
$165,000 and an option to purchase 25,000 shares of Common Stock at $3.75 per
share was granted. Of the 25,000 shares granted, 5,000 shares became fully
vested on January 27, 1998, 10,000 shares will become vested on September 1,
1999 and the remaining 10,000 shares will become vested on September 1, 2000. In
January 1999, Mr. Mendelsohn became the non-executive Chairman of the Company
and his employment agreement was replaced by a service agreement.

In December 1995, in connection with his employment agreement, the Company
granted Mr. Groenewoud an option to purchase 25,000 shares of Common Stock at
$8.50 per share. One-third of the option vested on October 1, 1996 and the
remaining two-thirds vests in monthly installments over the 24-month period
beginning on October 1, 1996, in each case based on Mr. Groenewoud's continued
employment during that time. In conjunction with the repricing of all of the
Company's stock options, Mr. Groenewoud's options were cancelled effective
December 19, 1997 and replaced with identical repriced New Options having an
exercise price of $3.125 per share. On January 27, 1998, Mr. Groenewoud was
granted an option to purchase 11,000 shares of Common Stock at $3.75 per share
to be vested in monthly installments through October 1, 1998.

In connection with his employment agreement, in December 1995 the Company
granted Mr. Spiegler an option to purchase 36,000 shares of Common Stock at
$8.50 per share. One-third of the option vested on September 27, 1996 and the
remaining two-thirds vests in monthly installments over the 24-month period
beginning on September 27, 1996, in each case based on Mr. Spiegler's continued
employment during that time. In conjunction with the repricing of all of the
Company's stock options, Mr. Spiegler's options were cancelled effective
December 19, 1997 and replaced with identical repriced New Options having an
exercise price of $3.125 per share.

At various times during 1996 and 1997, Joseph Storella, Marc Feinberg,
Mitchell Goldberg and Seymour Hyden entered into three-year employment
agreements with the Company for the position of Vice President-Operations; Vice
President-Quality Assurance and Regulatory Affairs; Vice President-Sales and
Marketing; and Vice President-Scientific and Technical Affairs; respectively.
Messrs. Storella's, Feinberg's and Goldberg's and Dr. Hyden's employment
agreements provide for a base annual salary of $130,000, $130,000, $110,000 and
$130,000, respectively, which may be increased annually at the discretion of the
Board of Directors, as well as stock options and a customary benefits package.
Under Mr. Goldberg's employment agreement, he received a sign-on bonus of
$10,000. In addition, he may be eligible for certain performance-based bonuses
in 1997 in the amount of $5,000 per quarter in the event that the Company
reaches certain projected sales goals, which amount shall be proportionally
increased in the event that such goals are exceeded, and $10,000 per quarter in
1998 in the event that such projections are met. In January, 1998, Mr. Goldberg
was paid a sales bonus of $10,000 regarding the 1997 sales performance. In April
1998, Mr. Goldberg was paid a sales bonus of $10,000 regarding the quarter ended
March 31, 1998 sales performance.

The term of each of Messrs. Storella's, Feinberg's and Goldberg's and Dr.
Hyden's employment agreement may be extended. The employment agreements of
Messrs. Storella, Feinberg and Goldberg and Dr. Hyden prohibit them from (i)
competing with the Company for one year following termination of employment with

the Company and (ii) disclosing confidential information or trade secrets in any
unauthorized manner. If Mr. Goldberg is discharged without cause (as defined in
his agreement), the Company shall continue to pay Mr. Goldberg his then current
salary for the lesser of six months or the remainder of the agreed upon
employment period. If Messrs. Storella or Feinberg or Dr. Hyden is discharged
without cause (as defined in such employee's agreement), the Company shall
continue to pay such employee his then current salary for a period of six
months.

In 1996, in connection with his employment agreement, the Company granted
Mr. Storella an option to purchase 36,000 shares of Common Stock at $9.13 per
share. One-third of the option vests on May 20, 1997 and the remaining
two-thirds vests in monthly installments over the 24-month period beginning on
May 20, 1997, in each case based on Mr. Storella's continued employment during
that time. In conjunction with the repricing of all of the Company's stock
options, Mr. Storella's options were cancelled effective December 19, 1997 and
replaced with identical repriced New Options having an exercise price of $3.125
per share.

In 1996, in connection with his employment agreement, the Company granted
Mr. Feinberg an option to purchase 36,000 shares of Common Stock at $8.50 per
share. One-third of the option vests on October 14, 1997 and the remaining
two-thirds vests in monthly installments over the 24-month period beginning on
October 14, 1997, in each case based on Mr. Feinberg's continued employment
during that time. In conjunction with the repricing of all of the Company's
stock options, Mr. Feinberg's options were cancelled effective December 19, 1997
and replaced with identical repriced New Options having an exercise price of
$3.125 per share.

In 1997, in connection with his employment agreement, the Company granted
Mr. Goldberg an option to purchase 36,000 shares of Common Stock at $8.50 per
share. One-third of the option vests on March 17, 1998 and the remaining
two-thirds vests in monthly installments over the 24-month period beginning on
March 17, 1998, in each case based on Mr. Goldberg's continued employment during
that time. In conjunction with the repricing of all of the Company's stock
options, Mr. Goldberg's options were cancelled effective December 19, 1997 and
replaced with identical repriced New Options having an exercise price of $3.125
per share.

In 1997, in connection with his employment agreement, the Company granted
Dr. Hyden an option to purchase 36,000 shares of Common Stock at $8.50 per
share. One-third of the option vests on March 31, 1998 and the remaining
two-thirds vests in monthly installments over the 24-month period beginning on
March 31, 1998, in each case based on Dr. Hyden's continued employment during
that time. In conjunction with the repricing of all of the Company's stock
options, Mr. Hyden's options were cancelled effective December 19, 1997 and
replaced with identical repriced New Options having an exercise price of $3.125
per share. Dr. Hyden terminated his employment with the Company in March 1999.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Scientific Advisory Board

In March 1997, the Board of Directors authorized the formation of a
Scientific Advisory Board to be chaired by Dr. Rowe. The Scientific Advisory
Board has not held a meeting to date, but when it commences its activities, the
Board of Directors has authorized the following compensation plan: as Chairman,
Dr. Rowe will receive an initial stipend of $30,000 along with options to
purchase 15,000 shares of Common Stock having an exercise price equal to the
fair market value on the date of the grant. Dr. Rowe will also receive an annual
grant of an option to purchase 5,000 shares of Common Stock as well as an option
to purchase 1,000 shares of Common Stock for each meeting attended, with a
maximum of four meetings per year. Each other member of the Scientific Advisory
Board will receive an option to purchase 2,000 shares of Common Stock on the
date of joining the board, a stipend of $1,000 per meeting and a grant of an
option to purchase 750 shares of Common Stock for each meeting attended, with a
maximum of four meetings per year.

PROPOSAL NO. 2--APPROVAL OF CERTAIN AMENDMENTS
TO THE COMPANY'S 1995 STOCK INCENTIVE PLAN
AND APPROVAL OF CERTAIN DISCRETIONARY AWARDS

The Board of Directors has unanimously adopted, subject to stockholder
approval, certain amendments to the 1995 Plan which would (i) increase the
number of shares of Common Stock that may be issued thereunder from 750,000
shares to 950,000 shares, (ii) provide that directors are eligible to receive
periodic grants by the Board of Directors, in its sole discretion, of options,
(iii) reduce the annual grant of options to non-employee directors who were
directors of the Company after September 1, 1995 from 10,000 to 5,000 shares,
and (d) limit the number of options which may be granted to any employee under
the 1995 Plan during any calendar year to 100,000 so that options granted under
the Plan will be exempt from the deduction limitation under Section 162(m) of
the Internal Revenue Code of 1986, as amended (the "Code"). In May 1998, the
Company's stockholders approved an amendment to increase the number of shares of
Common Stock from 550,000 shares to 750,000 shares. As of March 16, 1999, the
number of shares available for future grants under the 1995 Plan was 4,463, with
no shares of Common Stock having been issued under the 1995 Plan.

The 1995 Plan, as amended hereby, was adopted by the Board of Directors for
the purpose of securing for the Company and its stockholders the benefits of
ownership of Company stock options by all directors ("Directors") including
directors who are not employees and who were not directors on or before
September 1, 1995 ("Eligible Directors"), directors who are not employees and
who were directors of the Company on or before September 1, 1995 ("Pre-IPO
Directors"), officers, other key employees and consultants ("Key Employees") of
the Company (and any subsidiary corporations) who are expected to contribute to
the Company's future growth and success. At March 16, 1999, the Company's nine
Directors, including four Eligible Directors, three Pre-IPO Directors and
approximately 58 Key Employees (excluding consultants) were eligible to
participate in the 1995 Plan. No award may be granted under the 1995 Plan after
September 14, 2005.

The Committee (as defined below) may in its sole discretion grant options
to Key Employees and (if the Amendments are approved by the stockholders)
Directors, and must grant options to the Company's Eligible Directors and
Pre-IPO Directors, subject to specified terms and conditions and in accordance
with a specified formula. Options granted to Key Employees (other than
consultants) may be either incentive stock options ("ISOs") meeting the
requirements of Section 422 of the Code, or non-qualified stock options
("NQSOs") not meeting the requirements of Section 422 of the Code. Options
granted to Directors and consultants are NQSOs.

The 1995 Plan provides that it may be administered by the Board of
Directors or, except with regard to director awards, a committee appointed by
the Board. The Board has designated the Stock Option Committee (the "Committee")
to administer the 1995 Plan. Subject to the terms of the 1995 Plan, the
Committee will determine the Key Employees who will receive grants of options,
the number of shares of Common Stock subject to each option, the grant date, the
expiration date and the terms and conditions for the options. Options granted to
Eligible Directors and Pre-IPO Directors are governed by the formula discussed
below. The Committee has the authority to construe and interpret the provisions
of the 1995 Plan and the options granted thereunder. Each grant of options are
to be evidenced by a stock option agreement executed by the Company and the
Director, Eligible Director, Pre-IPO Director or Key Employee, as the case may
be, at the time of grant, in accordance with the terms and conditions of the
1995 Plan.

An option granted to a Key Employee expires on the date determined by the
Committee, which date may not exceed ten years from the date the option is
granted (or, in the case of a Ten Percent Stockholder (as defined below) who
receives ISOs, five years). Unless otherwise specified by the Committee for a
particular grant, options granted to Key Employees vest equally over four years,
commencing on the first anniversary of the date of grant, in each case assuming
the recipient has been continuously employed by the Company or any subsidiary
during that time.

If a Key Employee's employment or service with the Company or its
subsidiaries is terminated for any reason other than death or disability or a
discharge for cause, any outstanding option, to the extent that it was
exercisable on the date of such termination, may be exercised by the holder
within three months after such termination (or such shorter time as may be
specified by the Committee), but in no event later than the expiration of the
option. If a Key Employee dies or becomes totally and permanently disabled while
an employee of the Company or a subsidiary, or dies within three months after
the Key Employee ceases to be such an employee, any outstanding option, to the
extent that it has vested may be exercised by the Key Employee (his estate, or
by the person to whom the option is transferred by will or the laws of descent
and distribution, as the case may be) within the period of one year after the
date of death or the date the Key Employee ceases to be an employee because of
such disability (or within such lesser period as may be specified by the
Committee). If a Key Employee is discharged for "cause" (as defined in the 1995
Plan), the right of such Key Employee to exercise an option will terminate
immediately upon cessation of such services.

The formula pursuant to which Eligible Directors are granted options under
the 1995 Plan provides that (if the Amendments are approved by the stockholders)
on the first business day following the 1999 annual meeting of stockholders and
the first business day following annual meeting of stockholders, each person who
is elected as a director after that meeting and is an Eligible Director, and
each person who continues to serve as director after that meeting and is an
Eligible Director, shall be granted an option to purchase 5,000 shares of Common
Stock (the "Eligible Director Options") in recognition of service as a director.
Each person who is elected as a director at any time other than at an Annual
Meeting of Stockholders shall receive options to purchase 5,000 shares of Common
Stock on the date of such election in lieu of the Eligible Director Options to
be granted after the Company's next Annual Meeting and automatically would grant
to each Pre-IPO Director on the first business day following the 1998 Annual
Meeting of Stockholders and on the first business day following each successive
Annual Meeting of Stockholders (to the extent such Pre-IPO Director continues to
serve as a director after that meeting), an option under the 1995 Plan to
purchase 5,000 shares of Common Stock (the "Pre-IPO Director Options" and,
together with the Eligible Director Options, the "Director Options"). Pursuant
to the Amendments, the Director Options are being reduced, subject to
stockholder approval, from an annual option grant of options to purchase 10,000
shares to options to purchase 5,000 shares. Director Options expire ten years
from the date of grant and vest ratably over three years commencing on the first
anniversary of the date of grant, assuming that the recipient continuously
serves as a director during that time. All vested options granted to the
directors under the 1995 Plan remain exercisable until their expiration date.

The 1995 Plan, as amended hereby, provides that the Company may, in the
sole discretion of the Board of Directors, grant additional options to the
Company's Directors. The terms of such option shall be such terms as shall be
determined by the Board of Directors and as set forth in the option agreement,
although the expiration date shall not exceed ten years from the date that the
option is granted.

Options granted under the 1995 Plan must be exercised within ten years of
grant date, except that an ISO granted to a person owning more than 10% of the
total combined voting power of all classes of stock of the Company or of any
parent or subsidiary of the Company (a "Ten Percent Stockholder") must be
exercised within five years of the grant date. The exercise price of each option
granted under the 1995 Plan shall be the fair market value per share of the
Common Stock on the date the option is granted.

For ISOs granted to a Ten Percent Stockholder, the exercise price cannot be
less than 110% of the fair market value (the "Fair Value") per share of Common
Stock. The exercise price may be paid in cash (by check) by transferring shares
of Common Stock owned by the option holder and having a Fair Value on the date
of surrender equal to the aggregate exercise price of the option, or solely with
respect to options granted to Key Employees by cash payments in installments or
pursuant to a full recourse promissory note, in either case, upon the terms and
conditions as the Committee determines. Upon the exercise of any option, the
Company is required to comply with all applicable withholding tax requirements.

Subject to the stockholders' approval of the Amendments, the maximum number
of options which may be granted to any employee under the 1995 Plan during any
calendar year shall not exceed 100,000.

The Board may amend or terminate the 1995 Plan at any time and in any
respect, except that the Board or the Committee cannot, without the approval of
the stockholders of the Company, amend the 1995 Plan if stockholder approval is
required pursuant to Section 162(m) or 422, of the Code. No amendment of the
1995 Plan, without the option holder's consent, may adversely affect any options
previously granted him or her.

The table below indicates stock options that have been granted during the
1998 fiscal year under the 1995 Plan to (i) each person named in the Summary
Compensation Table appearing earlier in this Proxy Statement, (ii) all current
executive officers of the Company as a group, (iii) all current directors who
are not executive officers as a group and (iv) all employees of the Company,
including all current officers of the Company who are not executive officers of
the Company, as a group:

1995 Stock Incentive Plan Benefits Granted During Fiscal 1998

Name and Position Dollar Value ($)(1) Number of Shares
- ----------------- ------------------- -----------------

Barry R. Edwards........................................... 5,327 12,175
President and Chief Executive Officer
Max L. Mendelsohn.......................................... 6,847 15,650
Chairman
Cornel C. Spiegler......................................... 4,756 10,870
Chief Financial Officer and Vice President--Administration
Joseph A. Storella......................................... 4,375 10,000
Vice President - Operations
Marc M. Feinberg........................................... -- --
Vice President - Quality Assurance and Regulatory Affairs
Seymour Hyden, Ph.D........................................ -- --
Vice President - Scientific and Technical Affairs
Executive Officers as a Group.............................. 22,256 50,870
Non-Executive Officer Director Group ...................... 8,750 10,000
Non-Executive Officer Employee Group....................... 1,706 9,100

- --------------------------

(1) The closing price of Common Stock on the Nasdaq SmallCap Market on
March 16, 1999 was $2.4375. The dollar value listed is the excess, if
any, of the closing price of the Common Stock on March 16, 1999 over
the exercise price of the options.

Federal Income Tax Consequences

An optionee will not realize taxable income upon the grant of an option. In
general, the holder of an NQSO will realize ordinary income when the option is
exercised equal to the excess of the value of the stock over the exercise price
(i.e. the option spread), and the Company is entitled to a corresponding
deduction. If an option is exercised within six months after the date of grant
and if the optionee is subject to the six month restrictions on sale of Common
Stock under Section 16(b) of the Securities Exchange Act of 1934, as amended,
the optionee generally will recognize ordinary income on the date the
restrictions lapse, unless early income recognition election is made. Upon a
later sale of the stock, an optionee will realize capital gain or loss equal to
the difference between the selling price and the sum of the exercise price plus
the amount of the ordinary income recognized at the time of exercise. Subject to
the limitation under Section 162(m) of the Code (as described below), the
Company generally will be entitled to a deduction for federal income tax
purposes at the same time and in the same amount as the optionee is considered
to have realized ordinary income in connection with the exercise of option.

The holder of an ISO will not realize taxable income upon the grant or
exercise of an option (although the option spread is included in income for
purpose of the alternative minimum tax). If the stock acquired upon exercise of
the ISO is sold or otherwise disposed of within two years from the option grant
date or within one year from the exercise date, then, in general, gain realized
on the sale is treated as ordinary income to the extent of the option spread at
the exercise date, and the Company receives a corresponding deduction. Any
remaining gain is treated as capital gain. If such stock is sold after the
one-and-two-year holding periods described in the preceding sentence, then any
gain or loss realized upon the sale will be capital gain or loss and the Company
will not be entitled to a deduction. A special basis adjustment applies to
reduce the gain for alternative minimum tax purposes.

In general, Section 162(m) of the Code denies a publicly held corporation a
deduction for federal income tax purposes for compensation in excess of
$1,000,000 per year per person to its chief executive officer and the four other
officers whose compensation is disclosed in its proxy statement, subject to
certain exceptions. Options will generally qualify under one if these exceptions
if they are granted under a plan that states the maximum number of shares with
respect to which options may be granted to any employee during a specified
period and the plan under which options are granted is approved by stockholders
and is administered by a committee comprised of outside directors. The 1995 Plan
is intended to satisfy these requirements with respect to Options.

The Amendments to the 1995 Plan

The Board of Directors believes that the approval of the Amendments will
serve the best interest of the Company and its stockholders. The Board of
Directors believes that the amendment to increase the number of shares which may
be issued under the 1995 Plan will permit the Committee and the Board of
Directors to exercise needed flexibility in the administration of the 1995 Plan
and the granting of options thereunder. In addition, the Board of Directors
believes that the ability to grant additional options will help attract,
motivate and retain key employees who are in a position to contribute to the
successful conduct of the business and affairs of the Company as well as
stimulate in such individuals an increased desire to render greater service to
the Company. The Board of Director further believes that the amendments that
provide for the reduction of the annual grant of Director Options from 10,000
options to 5,000 options and the provision for discretionary option grants for
Directors will enable the Board of Directors to encourage continued service by
such individuals while recognizing particular efforts on the part of certain
individuals from time to time. The full text of the proposed amendments,
indicating the proposed language to be deleted or inserted, is attached hereto
as Appendix A.

Accordingly, the Board of Directors recommends that the stockholders
approve the following resolutions:

RESOLVED, that the 1995 Plan be amended by restating paragraph (a) of
Section 2 thereof to read in its entirety as follows:

"(a) Types of Awards. Under the Plan, the Company may in its sole
discretion grant, with respect to the Company's common stock, par value
$.01 per share ("Common Stock") Options ("Options") to key employees and
consultants (together, the "Key Employees") and to directors of the
Company (the "Directors"), each as authorized by action of the Board of
Directors of the Company (or, except in the case of grants to Directors,
a committee designated by the Board of Directors), and in addition to
the foregoing, the Company shall, subject to the terms and conditions
hereof, grant to each director of the Company who is not an employee and
who was not a director on or before September 1, 1995 (an "Eligible
Director") and to each director of the Company who is not an employee
and who was a director on or before September 1, 1995 (a "Pre-IPO
Director"), Options in accordance with the formula set forth in Section
7 hereof. As used in the Plan, an "Award" shall mean an Option and an

"Award Owner" shall mean the owner of an Option. Options granted
pursuant to the Plan to Key Employees (including 10% stockholders of the
Company and its Subsidiaries but excluding consultants) may be either
incentive stock options ("Incentive Stock Options") meeting the
requirements of Section 422 of the Internal Revenue Code of 1986, as
amended (the "Code"), or non-statutory options ("Non-Statutory Stock
Options"), which are not intended to or do not meet the requirements of
Code Section 422. All Options granted to Directors and consultants
pursuant to the Plan shall be only Non-Statutory Stock Options."

RESOLVED, that the 1995 Plan be amended by restating subparagraph (ii) of
paragraph (a) of Section 3 thereof to read in its entirety as follows:

"(ii) A Key Employee (other than a consultant) may be granted Incentive
Stock Options and/or Non-Statutory Stock Options. Directors and
consultants may only be granted Non-Statutory Stock Options. A Key
Employee or Director who has been granted an Award may, if he or she is
otherwise eligible, be granted one or more additional Awards if the
Committee shall so determine."

RESOLVED, that the Plan be amended by restating Section 4 thereof to read
in its entirety as follows:

"Subject to adjustment as provided in Section 13 below, the maximum
number of shares of Common Stock of the Company that may be issued and
sold pursuant to Options granted under the Plan is 950,000 shares in
the aggregate (one share per Option). The maximum number of shares of
Common Stock with respect to which Options may be granted under the
Plan to any Key Employee shall not exceed 100,000 shares during any
calendar year."

RESOLVED, that the 1995 Plan be amended by adding the following new
paragraph (h) to Section 6 thereof:

"(h) Except as set forth in Section 7, any Director of the Company
shall be granted Awards only if such person has been selected
for participation and the terms and provisions of such Awards
have been determined by the Board of Directors. The purchase
price per share of stock issuable upon the exercise of an
Option granted pursuant to this Section 6(h) shall be the Fair
Value on the date that such Option is granted. Each Award to a
Director shall expire on such date as the Board of Directors
shall determine on the date such Award is granted, but in no
event after the expiration of ten (10) years from the date on
which such Award is granted, and in all cases each Award shall
be subject to earlier termination as provided in the Plan.

If a Director dies while a director of the Company, the Options
that have been previously granted to that Director and that are
vested as of the date of such death may be exercised by the
administrator of the Director's estate, or by the person to
whom such Options are transferred by will or the laws of
descent and distribution. In no event, however, may any Option
be exercised after the expiration date of such Option. Any
Option or portion thereof that is not exercised during the
applicable time period specified above shall be deemed
terminated at the end of the applicable time period for
purposes of Section 4 hereof."

RESOLVED, that the 1995 Plan be amended by restating paragraph (a) of
Section 7 thereof to read in its entirety as follows:

"(a) Non-discretionary Grants. Notwithstanding anything to the contrary
contained in this Plan, Eligible Directors shall be granted Options
("Director Options") as follows: (i) immediately prior to the initial
public offering of shares of Common Stock, each Eligible Director shall
be granted 30,000 Director Options to purchase 30,000 shares of Common
Stock in the aggregate, subject to vesting as provided in Section 7(d)
below, (ii) on the first business day following the annual meeting of
stockholders of the Company to elect directors in 1996, and thereafter
until the first business day following the annual meeting of
stockholders of the Company to elect directors in 1998, each Eligible
Director shall be granted 10,000 Director Options to purchase 10,000
shares of Common Stock in the aggregate, subject to vesting as provided
in Section 7(d) below, and (iii) on the first business day following the
annual meeting of stockholders of the Company to elect directors in
1999, and thereafter on the first business day following each successive
annual meeting of stockholders, so long as Director Options remain
available for grant, each person who is elected as a director at that
meeting and is an Eligible Director, and each person who continues to
serve as a director after that meeting, and is an Eligible Director,
shall be granted 5,000 Director Options to purchase 5,000 shares of
Common Stock in the aggregate, subject to vesting as provided in Section
7(d) below, and (iv) on the first business day following the annual
meeting of stockholders to elect directors in 1998, and thereafter on
the first business day following each successive annual meeting of
stockholders, so long as Director Options remain available for grant,
each Pre-IPO Director who continues to serve as a director after that
meeting shall be granted 5,000 Director Options to purchase 5,000 shares
of Common Stock in the aggregate, subject to vesting as provided in
Section 7(d) below. Notwithstanding the foregoing, each person who is
elected as a director at any time after the date of the annual meeting
of stockholders and is an Eligible Director shall be granted, on the
effective date of such election, 5,000 Director Options to purchase
5,000 shares of Common Stock in the aggregate, subject to vesting as
provided in Section 7(d) below, so long as Director Options remain
available for grant. Such Director Options shall be granted in lieu of
the Director Options which would otherwise be granted to such Eligible
Director on the first business day following the next annual meeting of
the stockholders pursuant to the first sentence of this Section 7(a)."

RESOLVED, that the 1995 Plan be amended by replacing, except to the extent
appearing in the foregoing restrictions, all occurrences of the phrase "Key
Employee" appearing in the 1995 Plan and the exhibits thereto with the phrases
"Key Employee and Director" or "Key Employee or Director" as the context shall
reasonably dictate to effectuate the changes contemplated by the foregoing
resolutions.

Vote Required

The affirmative vote of the holders of a majority of the shares present in
person or represented by proxy and entitled to vote at the Annual Meeting is
required for adoption of the proposed Amendments to the 1995 Plan.

THE BOARD OF DIRECTORS DEEMS PORPOSAL NO. 2 TO BE IN THE BEST INTERESTS OF
THE COMPANY AND ITS STOCKHOLDERS AND RECOMMENDS A VOTE "FOR" APPROVAL THEREOF.

PROPOSAL NO. 3--APPROVAL OF AMENDMENT
TO THE CERTIFICATE OF INCORPORATION
TO INCREASE THE NUMBER OF AUTHORIZED SHARES

Under its Certificate of Incorporation, the Company is presently
authorized to issue 10,000,000 shares of Common Stock and 2,000,000 shares of
Preferred Stock. As of March 16, 1999, approximately 7,254,053 shares of Common
Stock, 9,000 shares of Series C Preferred, and 30,000 shares of Series D
Preferred were outstanding. An additional approximately 3,760,537 shares Common
Stock were reserved for issuance upon conversion of the Series C Preferred and
Series D Preferred and currently outstanding option and warrants. For the
reasons set forth below, the Company is requesting that the stockholders
authorize the amendment (the "Charter Amendment") to increase the number of
authorized shares of Common Stock by 7,000,000 shares to a total of 17,000,000
shares.

The Financing Commitment

On March 2, 1999, the Company entered into agreements to sell an aggregate
of 50,000 shares of Series D Preferred and warrants to purchase an aggregate of
625,000 shares of Common Stock (the "Warrants") to two investment funds, for an
aggregate purchase price of $5 million. Pursuant to the agreements, the initial
$3 million of Series D Preferred was sold on March 2, 1999 (the "First
Closing"). The remaining $2 million of Series D Preferred to be sold by the
Company (the "Second Closing") is scheduled to close prior to June 30, 1999 and
is contingent upon the authorization by the Company's stockholders of sufficient
additional shares of Common Stock to permit exercise in full of all shares of
Series D Preferred and all of the Warrants. The Series D Preferred is
convertible into Common Stock at $2.00 per share of Common Stock , subject to
certain antidilution protections. The Series D Preferred ranks senior to the
Common Stock, and junior to the Series C Preferred, upon liquidation or other
distribution of the Company's assets. Except as otherwise provided by law,
holders of the Series D Preferred vote with the holders of Common Stock on an
as-converted basis and are entitled to elect up to three directors. The Series D
Preferred has certain redemption rights and registration rights as well as
various customary terms and covenants for investments of this nature.

Purpose of the Charter Amendment

The Board of Directors recommends stockholder approval of the Charter
Amendment to amend the Company's Certificate of Incorporation to increase the
number of authorized shares of Common Stock to 17,000,000 shares. Upon
conversion of the outstanding shares of Series C Preferred, the conversion of
the shares of Series D Preferred issued at the First Closing , and exercise of
outstanding warrants and options of the Company, the Company will have
approximately 12,529,053 shares of Common Stock outstanding (assuming for
purposes of the Series C and Series D Preferred, a conversion price of $2.00 per
share). The authorization of additional shares would therefore be beneficial to
the Company in that it would permit the Company to consummate the Second
Closing, thereby providing the Company with additional funds for working capital
purposes deemed advisable by the Company's management and Board of Directors.
The additional seven million shares of Common Stock proposed to be authorized
should also provide the Company with sufficient flexibility to permit future
investments, should such investments be necessary or desirable, and the grant of
incentive and business-related stock options and warrants. Approval by the
Company's

stockholders of the increase in authorized shares is a condition of the Second
Closing for the final $2,000,000 investment in Series D Preferred. Stockholders
affiliated with Robert Fleming Inc., a 20.5% stockholder of the Company, are the
investors in the Second Closing. In addition, Messrs. Burr and Edwards, director
nominees, are officers of Fleming Capital Management, a subsidiary of Robert
Fleming, Inc.

Accordingly, the Board of Directors recommends that the stockholders
approve the following resolution:

RESOLVED, that subparagraph (a) of paragraph FOURTH of the Company's
Restated Certificate of Incorporation be amended and replaced on its entirety
with the following:

"FOURTH:

Section 1. Authorization.

(a) The total number of shares of all classes of stock which the
Corporation shall have the authority to issues is Nineteen Million (19,000,000)
shares, consisting of (i) Seventeen Million (17,000,000) shares of Common Tock,
$.01 par value per share (the "Common Stock"), and (ii) Two Million (2,000,000)
shares of designated preferred stock, $.01 par value per share (the "Preferred
Stock")."

If the Charter Amendment is approved, all or any part of the additional
authorized but unissued shares may be issued without further approval by the
stockholders, for such purposes and on such terms as the Board of Directors may
determine. Holders of the Company's Common Stock do not have any preemptive
rights to subscribe for the purchase of any shares of Common Stock, which means
that current stockholders do not have a prior right to purchase any new issue of
Common Stock to maintain their proportionate ownership interest in the Company.

Vote Required

The affirmative vote of the holders of a majority of the shares
outstanding is required for adoption of the proposed amendment to the
Certificate of Incorporation.

THE BOARD OF DIRECTORS DEEMS PROPOSAL NO. 3 TO BE IN THE BEST INTERESTS OF
THE COMPANY AND ITS STOCKHOLDERS AND RECOMMENDS A VOTE "FOR" APPROVAL THEREOF.

PROPOSAL NO. 4--RATIFICATION OF APPOINTMENT
OF INDEPENDENT ACCOUNTANTS

The stockholders will be asked to ratify the appointment of
PricewaterhouseCoopers LLP as the independent accountants of the Company for the
fiscal year ending December 31,1999. PricewaterhouseCoopers LLP audited the
financial statements of the Company for the fiscal year ended December 31, 1998.
A representative of PricewaterhouseCoopers LLP is expected to be present at the
Annual Meeting, will have an opportunity to make a statement if he or she
desires to do so and is expected to be available to respond to appropriate
questions from stockholders.

Vote Required

The affirmative vote of the holders of a majority of the shares present in
person or represented by proxy and entitled to vote at the Annual Meeting is
required for ratification of the selection of PricewaterhouseCoopers LLP as the
Company's independent accountants for the fiscal year ending December 31, 1999.

THE BOARD OF DIRECTORS DEEMS PROPOSAL NO. 4 TO BE IN THE BEST INTERESTS OF
THE COMPANY AND ITS STOCKHOLDERS AND RECOMMENDS A VOTE "FOR" APPROVAL THEREOF.

STOCKHOLDER PROPOSALS

All stockholder proposals which are intended to be presented at the Annual
Meeting of Stockholders of the Company to be held in 2000 must be received by
the Company no later than December 13, 1999 for inclusion in the Board of
Directors' proxy statement and form of proxy relating to that meeting.

OTHER BUSINESS

The Board of Directors knows of no other business to be acted upon at the
Annual Meeting. However, if any other business properly comes before the Annual
Meeting, it is the intention of the persons named in the enclosed proxy to vote
on such matters in accordance with their best judgment.

The prompt return of your proxy will be appreciated and helpful in
obtaining the necessary vote. Therefore, whether or not you expect to attend the
Annual Meeting, please sign the proxy and return it in the enclosed envelope.

By Order of the Board of Directors

CORNEL C. SPIEGLER
Secretary

Dated: April 12, 1999

APPENDIX A

Below is the text of the portion of the Company's 1995 Plan as proposed to
be amended pursuant to Proposal No. 2. Proposed language to the 1995 Plan which
is being submitted to the stockholders for approval is set forth underlined and
the language proposed to be deleted is set forth in brackets. The number and
heading of the sections which are proposed to be amended are set forth in bold
type.

1. Purpose.

The purpose of this plan (the "Plan") is to secure for Global
Pharmaceutical Corporation (the "Company"), and its stockholders, the benefits
arising from the ownership of stock options by directors, consultants and key
employees (including, without limitation, officers of the Company or
Subsidiaries (as defined in Section 18 hereof) who are expected to contribute to
the Company's future growth and success.

2. Types of Plan Benefits and Administration

(a) Types of Awards. Under the Plan, the Company may in its sole
discretion grant, with respect to the Company's common stock, par value $.01 per
share ("Common Stock") Options ("Options") to key employees and consultants
(together, the "Key Employees") and to directors of the Company (the
"Directors"), each as authorized by action of the Board of Directors of the
Company (or, except in the case of grants to Directors, a committee designated
by the Board of Directors), and in addition to the foregoing, the Company shall,
subject to the terms and conditions hereof, grant to each director of the
Company who is not an employee and who was not a director on or before September
1, 1995 (an "Eligible Director") and to each director of the Company who is not
an employee and who was a director on or before September 1, 1995 (a "Pre-IPO
Director"), Options in accordance with the formula set forth in Section 7
hereof. As used in the Plan, an "Award" shall mean an Option and an "Award
Owner" shall mean the owner of an Option. Options granted pursuant to the Plan
to Key Employees (including 10% stockholders of the Company and its Subsidiaries
but excluding consultants) may be either incentive stock options ("Incentive
Stock Options") meeting the requirements of Section 422 of the Internal Revenue
Code of 1986, as amended (the "Code"), or non-statutory options ("Non-Statutory
Stock Options"), which are not intended to or do not meet the requirements of
Code Section 422. All Options granted to Directors and consultants [Eligible
Directors and Pre-IPO Directors] pursuant to the Plan shall be only
Non-Statutory Stock Options.

3. Eligibility

(ii) A Key Employee (other than a consultant) may be granted Incentive
Stock Options and/or Non-Statutory Stock Options. Directors and consultants may
only be granted Non-Statutory Stock Options. A Key Employee or Director who has
been granted an Award may, if he or she is otherwise eligible, be granted one or
more additional Awards if the Committee shall so determine.

4. Stock Subject to Plan

Subject to adjustment as provided in Section[s] 13 [and 14] below, the
maximum number of shares of Common Stock of the Company that may be issued and
sold pursuant to Options granted under the Plan is [750,000] 950,000 shares in
the aggregate (one share per Option). The maximum number of shares of Common
Stock with respect to which Options may be granted under the Plan to any Key
Employee shall not exceed 100,000 shares during any calendar year.

6. Grants and Awards to Key Employees and Directors

(h) Except as set forth in Section 7, any Director of the Company shall be
granted Awards only if such person has been selected for participation and the
terms and provisions of such Awards have been determined by the Board of
Directors. The purchase price per share of stock issuable upon the exercise of
an Option granted pursuant to this Section 6(h) shall be the Fair Value on the
date that such Option is granted. Each Award to a Director shall expire on such
date as the Board of Directors shall determine on the date such Award is
granted, but in no event after the expiration of ten (10) years from the date on
which such Award is granted, and in all cases each Award shall be subject to
earlier termination as provided in the Plan.

An Award granted to a Director may be exercised, and payment shall be made
upon exercise of such Award, only to the extent that such Award has vested.
Awards shall vest in accordance with the schedule or terms set forth in the
Award agreement executed by the Award Owner and a duly authorized officer of the
Company. The Board of Directors may accelerate the vesting of any Option granted
pursuant to this Section 6(h). Unless otherwise determined by the Board of
Directors, if a Director ceases to serve as a director of the Company, the
Options that have been previously granted to that Director pursuant to this
Section 6(h) and that are vested as of the date of such cessation may be
exercised by the Director after the date such Director ceases to be a director
of the Company or Subsidiary. If a Director dies while a director of the
Company, the Options that have been previously granted to that Director and that
are vested as of the date of such death may be exercised by the administrator of
the Director's estate, or by the person to whom such Options are transferred by
will or the laws of descent and distribution. In no event, however, may any
Option be exercised after the expiration date of such Option. Any Option or
portion thereof that is not exercised during the applicable time period
specified above shall be deemed terminated at the end of the applicable time
period for purposes of Section 4 hereof.

7. Non-discretionary Formula Grants of Awards to Eligible Directors

(a) Non-discretionary Grants. Notwithstanding anything to the contrary
contained in this Plan, Eligible Directors shall be granted Options ("Director
Options") as follows: (i) immediately prior to the initial public offering of
shares of Common Stock, each Eligible Director shall be granted 30,000 Director
Options to purchase 30,000 shares of Common Stock in the aggregate, subject to
vesting as provided in Section 7(d) below, (ii) on the first business day
following the annual meeting of stockholders of the Company to elect directors
in 1996, and thereafter [on] until the first business day following [each
successive] the annual meeting of stockholders of the Company to elect directors
in 1998, each Eligible Director shall be granted 10,000 Director Options to
purchase 10,000 shares of Common Stock in the aggregate, subject to vesting as

provided in Section 7(d) below, and (iii) on the first business day following
the annual meeting of stockholders of the Company to elect directors in 1999,
and thereafter on the first business day following each successive annual
meeting of stockholders, so long as Director Options remain available for grant,
each person who is elected as a director at that meeting and is an Eligible
Director, and each person who continues to serve as a director after that
meeting, and is an Eligible Director, shall be granted 5,000 Director Options to
purchase 5,000 shares of Common Stock in the aggregate, subject to vesting as
provided in Section 7(d) below, and (iv) on the first business day following the
annual meeting of stockholders to elect directors in 1998, and thereafter on the
first business day following each successive annual meeting of stockholders, so
long as Director Options remain available for grant, each Pre-IPO Director who
continues to serve as a director after that meeting shall be granted 5,000
Director Options to purchase 5,000 shares of Common Stock in the aggregate,
subject to vesting as provided in Section 7(d) below. Notwithstanding the
foregoing, each person who is elected as a director at any time after the date
of the annual meeting of stockholders and is an Eligible Director shall be
granted, on the effective date of such election, [10,000] 5,000 Director Options
to purchase [10,000] 5,000 shares of Common Stock in the aggregate, subject to
vesting as provided in Section 7(d) below, so long as Director Options remain
available for grant. Such Director Options shall be granted in lieu of the
Director Options which would otherwise be granted to such Eligible Director on
the first business day following the next annual meeting of the stockholders
pursuant to the first sentence of this Section 7(a).

Change throughout the 1995 Plan

All occurrences of the phrase "Key Employee" appearing in the 1995 Plan
and the exhibits thereto are hereby changed to refer to "Key Employee and
Director" or "Key Employee or Director" as the context shall reasonably dictate
to effectuate the changes contemplated hereby.

GLOBAL PHARMACEUTICAL CORPORATION

This Proxy Is Solicited By The Board Of Directors For The
Annual Meeting Of Stockholders To Be Held On May 12, 1999

The undersigned, a stockholder of Global Pharmaceutical Corporation
(the "Corporation"), hereby constitutes and appoints Barry R. Edwards and Cornel
C. Spiegler and each of them, the true and lawful proxies and attorneys-in-fact
of the undersigned, with full power of substitution in each of them, to vote all
shares of Common Stock of the Corporation which the undersigned is entitled to
vote at the Annual Meeting of Stockholders of the Corporation to be held on
Wednesday, May 12, 1999, and at any and all adjournments or postponements
thereof, as follows:

(1) ELECTION OF DIRECTORS

|_| FOR the nominees listed below |_| WITHHOLDING AUTHORITY
(except as marked to the to vote for all the
contrary below) nominees listed below

(INSTRUCTIONS): To withhold authority to vote for any individual nominee,
strike a line through the nominee's name in the list below.)

Nominees: Robert L. Burr, Philip R. Chapman, Barry R. Edwards,
David J. Edwards, Gary Escandon, George F. Keane, Michael Markbreiter,
Max L. Mendelsohn, John W. Rowe and Udi Toledano

(2) PROPOSAL FOR THE APPROVAL OF CERTAIN AMENDMENTS TO THE COMPANY'S 1995 STOCK
INCENTIVE PLAN.

|_| FOR |_| AGAINST |_| ABSTAIN

(3) PROPOSAL FOR THE ADOPTION OF AN AMENDMENT TO THE CERTIFICATE OF
INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES.

|_| FOR |_| AGAINST |_| ABSTAIN

(4) PROPOSAL TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP

|_| FOR |_| AGAINST |_| ABSTAIN

(5) In their discretion, upon such other business as may properly come
before the meeting and any and all adjournments and postponements thereof.

(Continued on reverse side.)

(Continued)

Shares represented by this Proxy will be voted in accordance with the
instructions indicated in items 1, 2, 3, 4 and 5 above. If no instruction is
indicated, this Proxy will be voted FOR all listed nominees for directors and
FOR Proposals 2, 3 and 4.

Any and all proxies heretofore given by the undersigned are hereby
revoked.

Dated:_______________________

_____________________________

Please sign exactly as your
name(s) appear hereon. If
shares are held by two or more
persons each should sign.
Trustees, executors and other
fiduciaries should indicate
their capacity. Shares held by
corporations, partnerships,
associations, etc. should be
signed by an authorized
person, giving full title or
authority.

Please Date, Sign and Mail in the Enclosed Reply Envelope